NIH RePORTER
Cure8 regulatory brief
Why This Matters
Patients and clinicians struggle to predict relapse in ulcerative colitis because current endoscopic, histologic, and noninvasive biomarkers are imperfect. A tissue-based imaging and spatial-omics approach could identify molecular and structural markers that better indicate true mucosal healing and relapse risk.
Who Should Pay Attention
Researchers developing spatial-omics or imaging biomarkers, clinicians involved in endoscopic assessment of UC, and patients interested in research on relapse prediction and personalized monitoring.
Study Snapshot
Story typeRegulatory
Evidence typeFunded research project
Study statusFunded
Source depthResearch project record
What To Know
This is an NIH-funded research project to develop a whole-slide, multiscale, multimodal imaging platform that combines super-resolution microscopy, quantitative phase imaging, and multiplexed fluorescence to profile mucosal biopsies from people with ulcerative colitis.
The goal is to define structural and molecular signatures of mucosal healing and build computational models to predict which patients in remission are at higher risk of relapse.
The team will establish baseline structural and molecular profiles from UC patients and healthy controls, develop image analysis pipelines, and apply the platform to remission samples to seek features that differ between patients who remain in remission and those who relapse.
If successful, the platform could provide a more detailed tissue-based biomarker approach to assessing mucosal healing than current endoscopic or blood/stool tests, and might help personalize monitoring or treatment decisions in UC. This summary is grounded in the NIH project abstract and award record.
Keep In Mind
This record describes a funded research project (NIH Reporter project summary). It is a development and validation effort, not a report of completed clinical results; any predictive tools will require clinical validation before use in practice.
Source Details
Review the original publication for the complete reporting, methods, and context.
Funded research project
Evidence type derived from source or registry metadata.
PublicationNIH RePORTER
AuthorsYang Liu, Hongqiang Ma
InstitutionUNIVERSITY OF ILLINOIS AT URBANA-CHAMPAIGN
Study typeFunded Research Project
Indexed viaNIH RePORTER
Source typeFunded research record
PublishedSep 11, 2026, 12:00 AM
Content availableResearch project record
Funding disclosed by the source: National Institute of Biomedical Imaging and Bioengineering - R01EB037445 - $629,808
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Anti-TNF withdrawal or long-term treatment in ulcerative colitis (BIOSTOP): a multicentre open label, randomized controlled trial.
This trial directly informs a common clinical question: whether patients in deep remission can safely stop anti‑TNF therapy. Results show higher relapse risk after withdrawal, but many patients can be successfully...
Scientists Discover a Hidden Defect That Could Explain Why IBD Keeps Coming Back
The study suggests a hidden, early molecular defect that leaves intestinal cells primed to die even during clinical remission, which could help explain why flares recur. Measuring these molecular signals might eventually...
Cytokine biomarkers for response to IL23 p19 inhibition for inflammatory bowel diseases
Knowing biomarkers that predict who will respond to IL23 p19 inhibitors could help people with IBD avoid trial-and-error therapy choices. Understanding whether increasing risankizumab dosing after loss of response...